Brokerages Expect Stoke Therapeutics (NASDAQ:STOK) to Post ($1.02) Earnings Per Share

Share on StockTwits

Stoke Therapeutics (NASDAQ:STOK) has received an average broker rating score of 1.00 (Strong Buy) from the three analysts that cover the stock, Zacks Investment Research reports. Three analysts have rated the stock with a strong buy recommendation.

Brokerages have set a 12-month consensus price target of $39.00 for the company and are anticipating that the company will post ($1.02) EPS for the current quarter, according to Zacks. Zacks has also given Stoke Therapeutics an industry rank of 51 out of 256 based on the ratings given to related companies.

Several equities analysts recently weighed in on the company. JPMorgan Chase & Co. reissued a “sell” rating and set a $18.00 price objective on shares of ABB in a research report on Monday, July 15th. Canaccord Genuity assumed coverage on Slack in a research report on Monday, July 15th. They set a “buy” rating and a $40.00 price objective for the company. Credit Suisse Group set a $5.00 price objective on Maxar Technologies and gave the stock a “sell” rating in a research report on Monday, July 15th. Finally, Cowen reissued a “buy” rating on shares of Avrobio in a research report on Monday, July 15th.

In other news, major shareholder Apple Tree Partners Iv, L.P. purchased 1,388,889 shares of the stock in a transaction that occurred on Friday, June 21st. The shares were purchased at an average cost of $18.00 per share, for a total transaction of $25,000,002.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Rtw Investments, Lp purchased 555,556 shares of the stock in a transaction that occurred on Wednesday, June 19th. The shares were purchased at an average price of $18.00 per share, for a total transaction of $10,000,008.00. The disclosure for this purchase can be found here.

Shares of NASDAQ STOK traded down $0.74 during trading hours on Wednesday, hitting $22.71. 1,746 shares of the company’s stock were exchanged, compared to its average volume of 182,725. Stoke Therapeutics has a 1-year low of $22.84 and a 1-year high of $31.76.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases. Its lead product candidate, STK-001, to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics, Inc has a partnership with Invitae Corporation to offer epilepsy panel testing.

Read More: What is a Roth IRA?

Get a free copy of the Zacks research report on Stoke Therapeutics (STOK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Wedbush Securities Inc. Sells 160 Shares of Innospec Inc.
Wedbush Securities Inc. Sells 160 Shares of Innospec Inc.
Wedbush Securities Inc. Has $293,000 Position in China Mobile Ltd.
Wedbush Securities Inc. Has $293,000 Position in China Mobile Ltd.
Wedbush Securities Inc. Sells 1,062 Shares of Cedar Fair, L.P.
Wedbush Securities Inc. Sells 1,062 Shares of Cedar Fair, L.P.
Wedbush Securities Inc. Buys New Stake in Aquestive Therapeutics Inc
Wedbush Securities Inc. Buys New Stake in Aquestive Therapeutics Inc
7,019 Shares in D. R. Horton Inc  Bought by Wedbush Securities Inc.
7,019 Shares in D. R. Horton Inc Bought by Wedbush Securities Inc.
Wedbush Securities Inc. Has $294,000 Holdings in Office Properties Income Trust
Wedbush Securities Inc. Has $294,000 Holdings in Office Properties Income Trust


© 2006-2019 Ticker Report